Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction.

Lee,  Ki Young

doi:2011.12.4.190

J Korean Diabetes > Volume 12(4); 2011 > Article

Focused Issue

The Journal of Korean Diabetes 2011;12(4):190-193.
DOI: https://doi.org/10.4093/kcd.2011.12.4.190 Published online December 1, 2011.

간기능 이상 당뇨병환자에서 경구혈당강하제의 사용

이기영

Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction.

Ki Young Lee

Devision of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea. ylee@gilhospital.com

Abstract

The prevalence of type 2 diabetes mellitus in the Korea has increased dramatically over the past decade. Clinicians can prescribe the following six currently available classes of oral hypoglycemic agents: sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors and dipeptidyl peptidase inhibitors. The availability of various oral hypoglycemic agents has given rise to several adverse effects and may result in worse outcomes in patients with comorbid conditions such as liver dysfunction, renal impairment and heart failure. When taking a cross-sectional view of hepatic dysfunction, we find that hepatitis B and alcoholic liver disease are most prevalent in Korea. The use of oral hypoglycemic agents in type 2 diabetic patients with hepatic dysfunction requires many considerations.

Key Words: Type 2 diabetes mellitus, Liver diseases, Hypoglycemic agents, Oral administration